Last month, BrainStorm Cell Therapeutics, an Israeli bio-technology startup announced two major milestones: the company received a patent from the United States Patent Office its autologous stem cell technology called Nurown and it entered into an agreement with Massachusetts General Hospital to hold a Phase II clinical trial of Nurown....
Continue Reading >>










